Press Enter to search · Esc to close
Three new clinical analyses cut through the semaglutide and tirzepatide hype — quantifying real-world weight loss at one year, the muscle question lifters keep asking, and what happens when patients head into the OR.
The same peptide class that reshaped weight loss is now stacking evidence in kidney protection, fibrosis prevention, and transplant medicine. Here's what the data actually says.
Algorithms promise to engineer the perfect meal for your face, your physique, and your future. A new scoping review separates the signal from the marketing.
New 2025 data suggests GLP-1 receptor agonists are doing more than shrinking waistlines — with signals across the brain, kidneys, and operating room. Here's what the evidence actually says.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
The same peptide class everyone's whispering about in the locker room is showing up in neurology, nephrology, and orthopedic data. The signal looks real — but moderate, not miraculous.